PX-E-P8

PX-E-P8 is a synthetic **phenylxanthine derivative** developed as a dual-action drug for Parkinson's disease. It acts as both an **adenosine A2A receptor antagonist** and a **monoamine oxidase B (MAO-B) inhibitor**, making it a candidate for antiparkinsonian therapy. In preclinical studies, PX-E-P8 demonstrated the ability to cross the blood-brain barrier and exhibited desirable pharmacokinetic properties following intraperitoneal administration in rats. It showed moderate potency for both A2AR antagonism (Ki for human A2AR: 850 nM) and MAO-B inhibition (Ki for human MAO-B: 630 nM), and significantly reduced haloperidol-induced catalepsy in animal models, confirming its therapeutic potential. PX-E-P8 belongs to the PX-E chemical series, which, alongside PX-D derivatives, aims to offer both symptomatic and neuroprotective benefits for Parkinson’s disease via dual mechanisms of action[1][3].

Brand names

PX-E-P8PX-E-P-8PX-E-P 8

Other names

PX-E-P8PX-E-P-8PX-E-P 8